Investors

At this moment, Pharmamel is at a key stage in its growth and development, both corporately and scientifically, as the company has begun the process to list on BME Scaleup by signing a strategic agreement with the registered advisor Armanext and entering the pre-market environment of Bolsa y Mercados Españoles (BME), where Pharmamel is expected to go public in the fourth quarter of 2024. On the scientific front, the company faces the significant challenge of completing an international, multicenter phase IIB/III clinical trial. Conducting this trial represents an important inflection point of value for Pharmamel, as obtaining positive results in this phase IIB/III trial, in addition to the excellent results obtained in phase 2 studies, will likely grant Pharmamel and its shareholders an increase in the valuation of the listed company, and the potential pre-licensing of the new intravenous melatonin injectable and the monetization of the drug with the likely “Fast Track” application. To fully finance the phase IIB/III clinical trial in Europe and the USA in accordance with EMA and FDA regulations and bring the drug to market, Pharmamel is launching a new pre-IPO capital increase round on Capital Cell, a platform regulated by CNMV, at a pre-money valuation of €37,000,000 before going public on BME Scaleup with an estimated initial listing valuation of €45,000,000.

This round is expected to be complemented by CDTI, NextGenerationEU, ENISA, and other grants for which the company has already applied, in addition to the participation of private and specialized investors, as well as public-private investment funds, with which the company has already signed pre-investment agreements/LOI, within a period of 6 to 12 months. This pre-IPO capital increase includes both retail investors through the CNMV-regulated platform, Capital Cell, as well as institutional investors, family offices, and venture capital firms. Once this capital increase round (with a minimum target of €2,000,000) is completed, the company plans to list on BME Scaleup by the end of 2024. The decision to go public is not only aimed at positioning the company but also at offering transparency, visibility, and reputation, as well as providing a clear exit route for investors and the opportunity to raise capital in financial markets. It is important to note that Pharmamel’s corporate strategy is not simply limited to listing on BME Scaleup; rather, the IPO is considered a tool and not an end in itself. Therefore, Pharmamel’s corporate plan includes the ambition to scale to the next level of the stock market, specifically to BME Growth or Euronext Access by 2026. This timeframe is strategically selected, as by then, Pharmamel will have completed and obtained the results of the first clinical phase of phase III trials, which will presumably increase the company’s valuation and open up the possibility of licensing or pre-licensing its technology to the pharmaceutical industry. With these significant events, the corporate strategy consists of scaling to the next level of the stock market, either by transitioning to BME Growth or by listing on the European market, Euronext.